| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/22/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/21/2023 | 530.52% | Benchmark | $4 → $1 | Maintains | Speculative Buy |
| 09/21/2023 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 09/21/2023 | — | Cantor Fitzgerald | Downgrades | Overweight → Neutral | |
| 08/22/2023 | 1161.03% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 08/15/2023 | 1161.03% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 1161.03% | Cantor Fitzgerald | → $2 | Reiterates | Overweight → Overweight |
| 06/23/2023 | 2422.07% | Benchmark | $4 → $4 | Reiterates | Speculative Buy → Speculative Buy |
| 05/16/2023 | 1161.03% | Cantor Fitzgerald | $3 → $2 | Maintains | Overweight |
| 05/15/2023 | 2422.07% | BTIG | $11 → $4 | Maintains | Buy |
| 03/30/2023 | 6835.69% | BTIG | → $11 | Maintains | Buy |
| 03/24/2023 | 2422.07% | Benchmark | $6 → $4 | Maintains | Buy |
| 02/13/2023 | 7466.2% | BTIG | $12 → $12 | Maintains | Buy |
| 04/28/2022 | 7466.2% | BTIG | → $12 | Maintains | Buy |
| 03/14/2022 | 2422.07% | B. Riley Securities | $6 → $4 | Maintains | Buy |
| 03/08/2022 | 1791.55% | Cantor Fitzgerald | $5 → $3 | Maintains | Overweight |
| 09/27/2021 | 4944.14% | Roth Capital | $2.5 → $8 | Upgrades | Neutral → Buy |
| 08/10/2021 | 1476.29% | Roth Capital | $4 → $2.5 | Maintains | Neutral |
| 07/01/2021 | 4944.14% | Guggenheim | → $8 | Initiates Coverage On | → Buy |
| 06/01/2021 | 6205.17% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 03/30/2021 | 9357.76% | B. Riley Securities | → $15 | Initiates Coverage On | → Buy |
| 03/12/2021 | 8727.24% | BTIG | → $14 | Initiates Coverage On | → Buy |
| 11/18/2019 | 1161.03% | HC Wainwright & Co. | $4 → $2 | Maintains | Buy |
| 11/14/2019 | — | Benchmark | Initiates Coverage On | → Speculative Buy | |
| 05/14/2019 | — | Roth Capital | Initiates Coverage On | → Buy | |
| 05/10/2019 | 2422.07% | HC Wainwright & Co. | → $4 | Initiates Coverage On | → Buy |
What is the target price for Seelos Therapeutics (SEEL)?
The latest price target for Seelos Therapeutics (NASDAQ: SEEL) was reported by Guggenheim on September 22, 2023. The analyst firm set a price target for $0.00 expecting SEEL to fall to within 12 months (a possible -100.00% downside). 13 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Seelos Therapeutics (SEEL)?
The latest analyst rating for Seelos Therapeutics (NASDAQ: SEEL) was provided by Guggenheim, and Seelos Therapeutics downgraded their neutral rating.
When is the next analyst rating going to be posted or updated for Seelos Therapeutics (SEEL)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Seelos Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Seelos Therapeutics was filed on September 22, 2023 so you should expect the next rating to be made available sometime around September 22, 2024.
Is the Analyst Rating Seelos Therapeutics (SEEL) correct?
While ratings are subjective and will change, the latest Seelos Therapeutics (SEEL) rating was a downgraded with a price target of $0.00 to $0.00. The current price Seelos Therapeutics (SEEL) is trading at is $0.16, which is out of the analyst's predicted range.